查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1298097

CAR-T細胞治療市場、份額、規模、趨勢、行業分析報告，按目標抗原（CD19/CD22、BCMA等）、按適應症、按地區、細分市場預測，2023-2032年

CAR-T Cell Therapy Market Share, Size, Trends, Industry Analysis Report, By Target Antigen (CD19/CD22, BCMA, and Others); By Indication; By Region; Segment Forecast, 2023 - 2032
出版日期: | 出版商: Polaris Market Research | 英文 119 Pages | 商品交期: 最快1-2個工作天內

價格

根據Polaris Market Research的最新研究，預計到2032年，全球CAR-T細胞治療市場規模將達到1186.8068億美元。 該報告提供了對當前市場動態的詳細見解，並對未來市場增長進行了分析。

利用免疫系統對抗癌症，CAR-T 細胞療法市場出現了顯著增長。 這種突破性的方法修改患者自身的 T 細胞（一種白細胞），以在其表面表達嵌合抗原受體 (CAR)。 CAR 使 T 細胞能夠識別並靶向癌細胞內的特定抗原，從而導致癌細胞被破壞。 CAR-T療法在治療某些血液惡性腫瘤方面顯示出有希望的結果，並且正在研究其在其他類型癌症中的潛力。

CAR-T 療法包括從患者血液中提取 T 細胞，並在實驗室中對它們進行基因改造，以產生與癌細胞中豐富的蛋白質結合的受體。 然後大量生產這些經過修飾的 CAR-T 細胞並給予患者。 通過增強 T 細胞發現和攻擊癌細胞的能力，CAR-T 療法有可能徹底改變癌症治療。

然而，COVID-19 大流行正在影響 CAR-T 細胞治療市場。 供應鏈關閉和中斷導致 CAR-T 細胞製造所需原材料的生產和供應出現延誤和中斷。 因此，生命科學和生物製藥公司面臨著等待用於 CAR-T 細胞製造的新原材料的挑戰。 我們正在努力解決這些供應鏈問題，並確保原材料的穩定供應，以支持在此困難時期的 CAR-T 細胞製造。

CAR-T 細胞治療市場報告亮點

CD19/CD22是市場份額最大的CAR-T細胞療法。 它在治療白血病和淋巴瘤方面表現出出色的臨床效果，已獲得監管部門批准，並已被證明可有效實現患者緩解。

DLBCL（瀰漫性大B細胞淋巴瘤）是CAR-T細胞治療市場的一個突出適應症，佔據了很大的市場份額。 這種快速生長的 B 細胞來源的癌症是一種影響淋巴系統的非霍奇金淋巴瘤。

在癌症發病率上升和生物技術行業增長的推動下，北美將引領市場。 因此，該地區對癌症治療的需求也在增加。

全球市場參與者包括：Amgen（美國）、Bellicum Pharmaceuticals（美國）、Bluebird Bio（美國）、Caribou Biosciences（美國）、Celgene、Cellectis、Celyad、Gilead Sciences、Intellia Therapeutics、Johnson &Johnson、Merck KGaA、Nanjing Legend Biotechnology、Noile-Immune Biotech、Novartis International AG、Pfizer Inc.、Sangamo Therapeutics、Servier Laboratories

內容

第一章簡介

第 2 章執行摘要

第三章研究方法

第四章全球 CAR-T 細胞治療市場洞察

  • CAR-T細胞治療市場-行業概況
  • CAR-T細胞療法市場動態
    • 驅動因素和機遇
      • 人們對 CAR-T 細胞療法的認識不斷提高
      • 癌症治療中對理想治療方法的需求增加
    • 制約因素和問題
      • CAR-T細胞療法的高成本
  • 杵分析
  • CAR-T細胞治療行業的趨勢
  • 價值鏈分析
  • COVID-19 的影響分析

第五章全球 CAR-T 細胞治療市場（按目標抗原）

  • 主要發現
  • 簡介
  • CD19/CD22
  • BCMA（B 細胞成熟抗原）
  • 其他（MUC16、L1CAM、ROR1、EGFRvIII、PSCA、NKR-2、IL13Ra2、LewisY）

第 6 章全球 CAR-T 細胞治療市場（按適應症）

  • 主要發現
  • 簡介
  • DLBCL
  • 全部
  • CLL
  • MM
  • 佛羅裡達州
  • 乳腺疾病
  • 骨髓纖維化
  • MLL
  • 胸腺癌
  • 膠質母細胞瘤
  • 反洗錢
  • 其他

第 7 章全球 CAR-T 細胞治療市場（按地區）

  • 主要發現
  • 簡介
    • 2019-2032 年 CAR-T 細胞療法市場評估，地區
  • CAR-T 細胞治療市場 - 北美
    • 北美：2019-2032 年 CAR-T 細胞治療市場（按適應症）
    • 北美：2019-2032 年按目標抗原劃分的 CAR-T 細胞治療市場
    • CAR-T細胞治療市場-美國
    • CAR-T 細胞治療市場 - 加拿大
  • CAR-T 細胞治療市場 - 歐洲
    • 歐洲：2019-2032 年 CAR-T 細胞療法市場（按適應症）
    • 歐洲：2019-2032 年 CAR-T 細胞治療市場（按目標抗原）
    • CAR-T 細胞治療市場 - 英國
    • CAR-T 細胞治療市場 - 法國
    • CAR-T 細胞治療市場 - 德國
    • CAR-T 細胞治療市場 - 意大利
    • CAR-T 細胞治療市場 - 西班牙
    • CAR-T 細胞治療市場 - 荷蘭
    • CAR-T 細胞治療市場 - 俄羅斯
  • CAR-T 細胞治療市場 - 亞太地區
    • 亞太地區：CAR-T 細胞治療市場，按適應症劃分，2019-2032 年
    • 亞太地區：2019-2032 年按目標抗原劃分的 CAR-T 細胞治療市場
    • CAR-T細胞治療市場——中國
    • CAR-T 細胞治療市場 - 印度
    • CAR-T 細胞治療市場 - 馬來西亞
    • CAR-T 細胞治療市場 - 日本
    • CAR-T 細胞治療市場 - 印度尼西亞
    • CAR-T 細胞治療市場 - 韓國
  • CAR-T細胞治療市場-中東和非洲
    • 中東和非洲：2019-2032 年 CAR-T 細胞治療市場（按適應症）
    • 中東和非洲：2019-2032 年按目標抗原劃分的 CAR-T 細胞治療市場
    • CAR-T 細胞治療市場 - 沙特阿拉伯
    • CAR-T細胞治療市場——阿拉伯聯合酋長國
    • CAR-T 細胞治療市場 - 以色列
    • CAR-T 細胞治療市場 - 南非
  • CAR-T 細胞治療市場 - 拉丁美洲
    • 拉丁美洲：CAR-T 細胞治療市場，按適應症劃分，2019-2032 年
    • 拉丁美洲：2019-2032 年按目標抗原劃分的 CAR-T 細胞治療市場
    • CAR-T細胞治療市場——墨西哥
    • CAR-T 細胞治療市場 - 巴西
    • CAR-T細胞治療市場-阿根廷

第 8 章競爭格局

  • 擴張和收購分析
    • 擴展名
    • 收購
  • 夥伴關係/協作/協議/披露

第 9 章公司簡介

  • Amgen Inc.（US）
  • Bellicum Pharmaceuticals, Inc
  • Bellicum Pharmaceuticals, Inc.（US）
  • Bluebird Bio（US）
  • Caribou Biosciences, Inc.（US）
  • Cellectis
  • Celyad
  • Gilead Sciences, Inc.
  • Intellia Therapeutics
  • Johnson & Johnson
  • Merck KGaA
  • Nanjing Legend Biotechnology Co., Ltd
  • Noile-Immune Biotech
  • Novartis International AG
  • Pfizer Inc
  • Sangamo Therapeutics, Inc
  • Servier Laboratories
Product Code: PM1389

The global CAR-T cell therapy market size is expected to reach USD 118,680.68 million by 2032, according to a new study by Polaris Market Research. The report "CAR-T Cell Therapy Market Share, Size, Trends, Industry Analysis Report, By Target Antigen (CD19/CD22, BCMA, and Others); By Indication; By Region; Segment Forecast, 2023 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The CAR-T cell therapy market is experiencing significant growth as it utilizes the immune system to combat cancer. This groundbreaking approach involves modifying a patient's own T cells, a type of white blood cell, to express chimeric antigen receptors (CARs) on their surface. These CARs enable the T cells to recognize and target specific antigens in cancer cells, leading to their destruction. CAR-T therapy has shown promising results in treating specific blood malignancies and is being explored for its potential in other types of cancer.

In CAR-T treatment, T cells from the patient's blood are taken out and genetically modified in a lab to produce receptors that bind to proteins prevalent in cancer cells. Large quantities of these modified CAR-T cells are then produced and administered to the patient. By enhancing the T cells' ability to locate and attack cancer cells, CAR-T therapy has the potential to revolutionize cancer treatment.

However, the COVID-19 pandemic has impacted the CAR-T cell therapy market. Lockdowns and disruptions in the supply chain have resulted in delays and interruptions in the production and availability of raw materials needed for CAR-T cell manufacturing. This has created challenges for life science and biopharma companies, causing them to wait for new raw materials for CAR-T cell production. Efforts are underway to address these supply chain issues and ensure a steady supply of materials to support the manufacturing of CAR-T cells during these challenging times.

CAR-T Cell Therapy Market Report Highlights

CD19/CD22 is the CAR-T cell therapy with the largest market share. It has shown remarkable clinical results in leukemia and lymphoma treatment, gaining regulatory approval and proving effective in achieving patient remission.

DLBCL (Diffuse Large B-cell Lymphoma) is a prominent indication in the CAR-T cell therapy market, holding a significant market share. This fast-growing cancer of B-cell origin is a prevalent form of non-Hodgkin lymphoma affecting the lymphatic system.

North America is set to lead the market, driven by rising cancer incidence and the growing biotechnology industry. The region's demand for cancer treatments is increasing accordingly.

The global key market players include: Amgen Inc. (US), Bellicum Pharmaceuticals, Inc. (US), Bluebird Bio (US), Caribou Biosciences, Inc. (US), Celgene Corporation, Cellectis, Celyad, Gilead Sciences, Inc., Intellia Therapeutics, Johnson & Johnson, Merck KGaA, Nanjing Legend Biotechnology Co., Ltd., Noile-Immune Biotech, Novartis International AG, Pfizer Inc., Sangamo Therapeutics, Inc., Servier Laboratories.

Polaris Market Research has segmented the CAR-T Cell Therapy market report based on target antigen, indication, and region:

CAR-T Cell Therapy, Target Antigen Outlook (Revenue - USD Million, 2019 - 2032)

  • CD19/CD22
  • BCMA (B-Cell Maturation Antigen)
  • Others (MUC16, L1CAM, ROR1, EGFRvIII, PSCA, NKR-2, IL13Ra2, LewisY)

CAR-T Cell Therapy, Indication Outlook (Revenue - USD Million, 2019 - 2032)

  • DLBCL
  • ALL
  • CLL
  • MM
  • FL
  • Mastozytosis
  • Myeloid Fibrosis
  • MLL
  • Thymic Cancer
  • Glioblastoma
  • AML
  • Others

CAR-T Cell Therapy, Regional Outlook (Revenue - USD Million, 2019 - 2032)

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Austria
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Rest of Asia Pacific
  • Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Rest of Middle East & Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global CAR-T Cell Therapy Market Insights

  • 4.1. CAR-T Cell Therapy Market - Industry Snapshot
  • 4.2. CAR-T Cell Therapy Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Rise in awareness regarding CAR T-cell therapy
      • 4.2.1.2. Increase in demand of ideal therapeutics for treatment of cancer
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. High cost of CAR T-cell therapies
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTLE Analysis
  • 4.5. CAR-T Cell Therapy Industry trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global CAR-T Cell Therapy Market, by Target Antigen

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global CAR-T Cell Therapy, by Target Antigen, 2019-2032 (USD Million)
  • 5.3. CD19/CD22
    • 5.3.1. Global CAR-T Cell Therapy Market, by CD19/CD22, by Region, 2019-2032 (USD Million)
  • 5.4. BCMA (B-Cell Maturation Antigen)
    • 5.4.1. Global CAR-T Cell Therapy Market, by BCMA (B-Cell Maturation Antigen), by Region, 2019-2032 (USD Million)
  • 5.5. Others (MUC16, L1CAM, ROR1, EGFRvIII, PSCA, NKR-2, IL13Ra2, LewisY)
    • 5.5.1. Global CAR-T Cell Therapy Market, by Others (MUC16, L1CAM, ROR1, EGFRvIII, PSCA, NKR-2, IL13Ra2, LewisY), by Region, 2019-2032 (USD Million)

6. Global CAR-T Cell Therapy Market, by Indication

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
  • 6.3. DLBCL
    • 6.3.1. Global CAR-T Cell Therapy Market, by DLBCL, by Region, 2019-2032 (USD Million)
  • 6.4. ALL
    • 6.4.1. Global CAR-T Cell Therapy Market, by ALL, by Region, 2019-2032 (USD Million)
  • 6.5. CLL
    • 6.5.1. Global CAR-T Cell Therapy Market, by CLL, by Region, 2019-2032 (USD Million)
  • 6.6. MM
    • 6.6.1. Global CAR-T Cell Therapy Market, by MM, by Region, 2019-2032 (USD Million)
  • 6.7. FL
    • 6.7.1. Global CAR-T Cell Therapy Market, by FL, by Region, 2019-2032 (USD Million)
  • 6.8. Mastozytosis
    • 6.8.1. Global CAR-T Cell Therapy Market, by Mastozytosis, by Region, 2019-2032 (USD Million)
  • 6.9. Myeloid Fibrosis
    • 6.9.1. Global CAR-T Cell Therapy Market, by Myeloid Fibrosis, by Region, 2019-2032 (USD Million)
  • 6.10. MLL
    • 6.10.1. Global CAR-T Cell Therapy Market, by MLL, by Region, 2019-2032 (USD Million)
  • 6.11. Thymic Cancer
    • 6.11.1. Global CAR-T Cell Therapy Market, by Thymic Cancer, by Region, 2019-2032 (USD Million)
  • 6.12. Glioblastoma
    • 6.12.1. Global CAR-T Cell Therapy Market, by Glioblastoma, by Region, 2019-2032 (USD Million)
  • 6.13. AML
    • 6.13.1. Global CAR-T Cell Therapy Market, by AML, by Region, 2019-2032 (USD Million)
  • 6.14. Others
    • 6.14.1. Global CAR-T Cell Therapy Market, by Others, by Region, 2019-2032 (USD Million)

7. Global CAR-T Cell Therapy Market, by Geography

  • 7.1. Key findings
  • 7.2. Introduction
    • 7.2.1. CAR-T Cell Therapy Market Assessment, By Geography, 2019-2032 (USD Million)
  • 7.3. CAR-T Cell Therapy Market - North America
    • 7.3.1. North America: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
    • 7.3.2. North America: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
    • 7.3.3. CAR-T Cell Therapy Market - U.S.
      • 7.3.3.1. U.S.: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
      • 7.3.3.2. U.S.: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
    • 7.3.4. CAR-T Cell Therapy Market - Canada
      • 7.3.4.1. Canada: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
      • 7.3.4.2. Canada: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
  • 7.4. CAR-T Cell Therapy Market - Europe
    • 7.4.1. Europe: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
    • 7.4.2. Europe: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
    • 7.4.3. CAR-T Cell Therapy Market - UK
      • 7.4.3.1. UK: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
      • 7.4.3.2. UK: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
    • 7.4.4. CAR-T Cell Therapy Market - France
      • 7.4.4.1. France: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
      • 7.4.4.2. France: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
    • 7.4.5. CAR-T Cell Therapy Market - Germany
      • 7.4.5.1. Germany: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
      • 7.4.5.2. Germany: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
    • 7.4.6. CAR-T Cell Therapy Market - Italy
      • 7.4.6.1. Italy: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
      • 7.4.6.2. Italy: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
    • 7.4.7. CAR-T Cell Therapy Market - Spain
      • 7.4.7.1. Spain: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
      • 7.4.7.2. Spain: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
    • 7.4.8. CAR-T Cell Therapy Market - Netherlands
      • 7.4.8.1. Netherlands: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
      • 7.4.8.2. Netherlands: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
    • 7.4.9. CAR-T Cell Therapy Market - Russia
      • 7.4.9.1. Russia: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
      • 7.4.9.2. Russia: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
  • 7.5. CAR-T Cell Therapy Market - Asia Pacific
    • 7.5.1. Asia Pacific: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
    • 7.5.2. Asia Pacific: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
    • 7.5.3. CAR-T Cell Therapy Market - China
      • 7.5.3.1. China: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
      • 7.5.3.2. China: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
    • 7.5.4. CAR-T Cell Therapy Market - India
      • 7.5.4.1. India: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
      • 7.5.4.2. India: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
    • 7.5.5. CAR-T Cell Therapy Market - Malaysia
      • 7.5.5.1. Malaysia: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
      • 7.5.5.2. Malaysia: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
    • 7.5.6. CAR-T Cell Therapy Market - Japan
      • 7.5.6.1. Japan: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
      • 7.5.6.2. Japan: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
    • 7.5.7. CAR-T Cell Therapy Market - Indonesia
      • 7.5.7.1. Indonesia: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
      • 7.5.7.2. Indonesia: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
    • 7.5.8. CAR-T Cell Therapy Market - South Korea
      • 7.5.8.1. South Korea: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
      • 7.5.8.2. South Korea: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
  • 7.6. CAR-T Cell Therapy Market - Middle East & Africa
    • 7.6.1. Middle East & Africa: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
    • 7.6.2. Middle East & Africa: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
    • 7.6.3. CAR-T Cell Therapy Market - Saudi Arabia
      • 7.6.3.1. Saudi Arabia: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
      • 7.6.3.2. Saudi Arabia: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
    • 7.6.4. CAR-T Cell Therapy Market - UAE
      • 7.6.4.1. UAE: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
      • 7.6.4.2. UAE: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
    • 7.6.5. CAR-T Cell Therapy Market - Israel
      • 7.6.5.1. Israel: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
      • 7.6.5.2. Israel: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
    • 7.6.6. CAR-T Cell Therapy Market - South Africa
      • 7.6.6.1. South Africa: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
      • 7.6.6.2. South Africa: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
  • 7.7. CAR-T Cell Therapy Market - Latin America
    • 7.7.1. Latin America: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
    • 7.7.2. Latin America: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
    • 7.7.3. CAR-T Cell Therapy Market - Mexico
      • 7.7.3.1. Mexico: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
      • 7.7.3.2. Mexico: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
    • 7.7.4. CAR-T Cell Therapy Market - Brazil
      • 7.7.4.1. Brazil: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
      • 7.7.4.2. Brazil: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
    • 7.7.5. CAR-T Cell Therapy Market - Argentina
      • 7.7.5.1. Argentina: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
      • 7.7.5.2. Argentina: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)

8. Competitive Landscape

  • 8.1. Expansion and Acquisition Analysis
    • 8.1.1. Expansion
    • 8.1.2. Acquisitions
  • 8.2. Partnerships/Collaborations/Agreements/Exhibitions

9. Company Profiles

  • 9.1. Amgen Inc. (US)
    • 9.1.1. Company Overview
    • 9.1.2. Financial Performance
    • 9.1.3. Product Benchmarking
    • 9.1.4. Recent Development
  • 9.2. Bellicum Pharmaceuticals, Inc
    • 9.2.1. Company Overview
    • 9.2.2. Financial Performance
    • 9.2.3. Product Benchmarking
    • 9.2.4. Recent Development
  • 9.3. Bellicum Pharmaceuticals, Inc. (US)
    • 9.3.1. Company Overview
    • 9.3.2. Financial Performance
    • 9.3.3. Product Benchmarking
    • 9.3.4. Recent Development
  • 9.4. Bluebird Bio (US)
    • 9.4.1. Company Overview
    • 9.4.2. Financial Performance
    • 9.4.3. Product Benchmarking
    • 9.4.4. Recent Development
  • 9.5. Caribou Biosciences, Inc. (US)
    • 9.5.1. Company Overview
    • 9.5.2. Financial Performance
    • 9.5.3. Product Benchmarking
    • 9.5.4. Recent Development
  • 9.6. Cellectis
    • 9.6.1. Company Overview
    • 9.6.2. Financial Performance
    • 9.6.3. Product Benchmarking
    • 9.6.4. Recent Development
  • 9.7. Celyad
    • 9.7.1. Company Overview
    • 9.7.2. Financial Performance
    • 9.7.3. Product Benchmarking
    • 9.7.4. Recent Development
  • 9.8. Gilead Sciences, Inc.
    • 9.8.1. Company Overview
    • 9.8.2. Financial Performance
    • 9.8.3. Product Benchmarking
    • 9.8.4. Recent Development
  • 9.9. Intellia Therapeutics
    • 9.9.1. Company Overview
    • 9.9.2. Financial Performance
    • 9.9.3. Product Benchmarking
    • 9.9.4. Recent Development
  • 9.10. Johnson & Johnson
    • 9.10.1. Company Overview
    • 9.10.2. Financial Performance
    • 9.10.3. Product Benchmarking
    • 9.10.4. Recent Development
  • 9.11. Merck KGaA
    • 9.11.1. Company Overview
    • 9.11.2. Financial Performance
    • 9.11.3. Product Benchmarking
    • 9.11.4. Recent Development
  • 9.12. Nanjing Legend Biotechnology Co., Ltd
    • 9.12.1. Company Overview
    • 9.12.2. Financial Performance
    • 9.12.3. Product Benchmarking
    • 9.12.4. Recent Development
  • 9.13. Noile-Immune Biotech
    • 9.13.1. Company Overview
    • 9.13.2. Financial Performance
    • 9.13.3. Product Benchmarking
    • 9.13.4. Recent Development
  • 9.14. Novartis International AG
    • 9.14.1. Company Overview
    • 9.14.2. Financial Performance
    • 9.14.3. Product Benchmarking
    • 9.14.4. Recent Development
  • 9.15. Pfizer Inc
    • 9.15.1. Company Overview
    • 9.15.2. Financial Performance
    • 9.15.3. Product Benchmarking
    • 9.15.4. Recent Development
  • 9.16. Sangamo Therapeutics, Inc
    • 9.16.1. Company Overview
    • 9.16.2. Financial Performance
    • 9.16.3. Product Benchmarking
    • 9.16.4. Recent Development
  • 9.17. Servier Laboratories
    • 9.17.1. Company Overview
    • 9.17.2. Financial Performance
    • 9.17.3. Product Benchmarking
    • 9.17.4. Recent Development

List of Tables

  • Table 1 Global CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
  • Table 2 Global CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
  • Table 3 CAR-T Cell Therapy Market Assessment, By Geography, 2019-2032 (USD Million)
  • Table 4 North America: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
  • Table 5 North America: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
  • Table 6 U.S.: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
  • Table 7 U.S.: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
  • Table 8 Canada: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
  • Table 9 Canada: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
  • Table 10 Europe: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
  • Table 11 Europe: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
  • Table 12 UK: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
  • Table 13 UK: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
  • Table 14 France: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
  • Table 15 France: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
  • Table 16 Germany: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
  • Table 17 Germany: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
  • Table 18 Italy: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
  • Table 19 Italy: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
  • Table 20 Spain: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
  • Table 21 Spain: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
  • Table 22 Netherlands: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
  • Table 23 Netherlands: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
  • Table 24 Russia: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
  • Table 25 Russia: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
  • Table 26 Asia Pacific: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
  • Table 27 Asia Pacific: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
  • Table 28 China: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
  • Table 29 China: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
  • Table 30 India: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
  • Table 31 India: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
  • Table 32 Malaysia: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
  • Table 33 Malaysia: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
  • Table 34 Japan: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
  • Table 35 Japan: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
  • Table 36 Indonesia: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
  • Table 37 Indonesia: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
  • Table 38 South Korea: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
  • Table 39 South Korea: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
  • Table 40 Middle East & Africa: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
  • Table 41 Middle East & Africa: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
  • Table 42 Saudi Arabia: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
  • Table 43 Saudi Arabia: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
  • Table 44 UAE: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
  • Table 45 UAE: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
  • Table 46 Israel: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
  • Table 47 Israel: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
  • Table 48 South Africa: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
  • Table 49 South Africa: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
  • Table 50 Latin America: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
  • Table 51 Latin America: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
  • Table 52 Mexico: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
  • Table 53 Mexico: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
  • Table 54 Brazil: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
  • Table 55 Brazil: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
  • Table 56 Argentina: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
  • Table 57 Argentina: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)

List of Figures

  • Figure 1 Global CAR-T Cell Therapy Market, 2019-2032 (USD Million)
  • Figure 2 Integrated Ecosystem
  • Figure 3 Research Methodology: Top-Down & Bottom-Up Approach
  • Figure 4 Market by Geography
  • Figure 5 Porter's Five Forces
  • Figure 6 Market by Indication
  • Figure 7 Global CAR-T Cell Therapy Market, by Indication, 2022 & 2032 (USD Million)
  • Figure 8 Market by Target Antigen
  • Figure 9 Global CAR-T Cell Therapy Market, by Target Antigen, 2022 & 2032 (USD Million)
  • Figure 10 CAR-T Cell Therapy Market Assessment, By Geography, 2019-2032 (USD Million)
  • Figure 11 Strategic Analysis - CAR-T Cell Therapy Market